Outcome of patients admitted to the intensive care unit with newly diagnosed small cell lung cancer. 2002

Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
Department of Medical Oncology, Clinical Haematology and Palliative Care, The Royal Melbourne Hospital, Parkville 3050, Vic., Australia. dhmo-medoncregistrar@petermac.unimelb.edu.au

Patients with newly diagnosed small cell lung cancer (SCLC) may be considered for admission to an intensive care unit (ICU). Even though SCLC is highly responsive to chemotherapy, it is not clear whether patient outcomes justify the resource use of an ICU. This paper reports the results of a retrospective review of 20 newly diagnosed cases of SCLC who were admitted to one of three ICUs in Melbourne, Australia. Patients who had more than one negative prognostic factor did uniformly poorly, with no survivors beyond 4 months. Five patients were treated with chemotherapy whilst intubated and receiving mechanical ventilatory support. Two of these patients responded to chemotherapy and were extubated 4 days later. Both of these patients were alive and free of tumour recurrence 7 months later. In contrast, patients not treated with chemotherapy died early (within 40 days). We conclude that some patients with SCLC achieve a medium to long-term survival following treatment with chemotherapy instituted during or around the time of their admission to an ICU. The admission to an ICU of selected patients with SCLC may be justified, and prognostic indicators may be of benefit in making these difficult treatment decisions.

UI MeSH Term Description Entries
D007362 Intensive Care Units Hospital units providing continuous surveillance and care to acutely ill patients. ICU Intensive Care Units,Intensive Care Unit,Unit, Intensive Care
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
August 2018, Annals of intensive care,
Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
January 2013, Hippokratia,
Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
August 2013, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG,
Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
January 2002, Le Journal medical libanais. The Lebanese medical journal,
Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
January 2008, The European respiratory journal,
Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
September 2012, Lung cancer (Amsterdam, Netherlands),
Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
March 2016, Asia-Pacific journal of clinical oncology,
Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
March 2014, Medical oncology (Northwood, London, England),
Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
December 2009, Intensive care medicine,
Ross R Jennens, and Mark A Rosenthal, and Paul Mitchell, and Jeffrey J Presneill
January 2009, Annals of thoracic medicine,
Copied contents to your clipboard!